Muutke küpsiste eelistusi

E-raamat: Race to Commercialize Biotechnology: Molecules, Market and the State in Japan and the US

Teised raamatud teemal:
  • Formaat - PDF+DRM
  • Hind: 110,50 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
  • Raamatukogudele
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

This comparative study looks at the early development of biotechnology in the US and Japan. Drawing on primary and secondary sources it traces the historical roots of recombinant DNA technology, discusses the tensions between regulation and promotional policies and identifies the major actors and strategies that launched biotechnology in both countries. Developing several strands of theory in economic history, science and technology policy, the book proposes a simple model that relates the differences in the two countries' responses to variations in the availability of institutional, financial and organizational resources needed to commercialize the new technology.
List of illustrations
ix
Series editor's preface x
Preface and acknowledgements xii
Abbreviations xv
Introduction
1(17)
The approach
6(3)
National innovation systems and biotechnology
9(3)
The market for biotechnology products
12(5)
A road map
17(1)
Firms, technological regimes, and national innovation systems
18(16)
Introduction
18(1)
The firm as innovator
19(3)
Technological regimes and trajectories
22(6)
Biotechnology and the national innovation system
28(3)
Putting it all together
31(3)
Biotechnology and national innovation systems in the US and Japan
34(45)
Industry
34(13)
Research infrastructure
47(18)
Public policy
65(12)
Conclusions
77(2)
The emergence of commercial biotechnology in the US
79(40)
Introduction
79(2)
Institutional formation and knowledge creation (1930s--1976)
81(14)
Knowledge enhancement (1976--1983)
95(9)
Commercial take-off (1983--1990s)
104(13)
Conclusions
117(2)
The emergence of commercial biotechnology in Japan
119(28)
Introduction
119(2)
The origins of Japan's bioindustry: 1920--1980
121(9)
Biotechnology fever hits Japan (1980--1985)
130(7)
From bio-boom to bio-reality: alliance strategies and the shift to basic research (1985--present)
137(7)
Conclusions
144(3)
Conclusions
147(9)
Summary
147(2)
Biotechnology in the US and Japan
149(4)
Concluding thoughts
153(3)
Notes 156(26)
Index 182


Steven W. Collins is Associate Professor in the Interdisciplinary Arts and Sciences Program at the University of Washington.